Non-Segmental Vitiligo Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo
Verified date | December 2023 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to evaluate how safe and effective upadacitinib is in participants with non-segmental vitiligo. Adverse effects and change in disease activity will be assessed. Upadacitinib is being evaluated for the treatment of non-segmental vitiligo. The study will enroll approximately 160 participants aged 18-65 with non-segmental vitiligo in 5 treatment arms across 35 sites worldwide. Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24 weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. Participants who received study drug during the first 24 weeks, will continue to receive study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Status | Completed |
Enrollment | 185 |
Est. completion date | August 29, 2023 |
Est. primary completion date | January 13, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Clinical diagnosis of non-segmental vitiligo (NSV) and no segmental or localized vitiligo. - Participants with all of the following at Screening and Baseline. - Visits: = 0.5 F-VASI and = 5 total vitiligo area scoring index (T-VASI). - Participants who have had prior exposure to immunomodulatory biologic therapy, for any indications, but discontinued the biologic therapy prior to the first dose of study drug. Recommended washout periods for biologic therapies include = 4 weeks for etanercept; = 8 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and ixekizumab; = 16 weeks for secukinumab; and = 12 weeks for ustekinumab. For biologic therapies not specified, therapies must be discontinued at least 5 times the mean terminal elimination half-life of a drug or 3 months prior to Baseline, whichever is longer. Exclusion Criteria: - Participants with segmental or localized vitiligo. - Participants with other skin conditions that would interfere with evaluation of vitiligo, participants with uncontrolled thyroid disease, and participants with > 33% leukotrichia on the face or > 33% leukotrichia on the body (including face). - Participants previously treated with any topical or systemic janus kinase (JAK) inhibitor or permanent skin bleaching agents. - Participants treated with any systemic vitiligo therapy (e.g., methotrexate, mycophenolate mofetil, corticosteroids), supplemental vitiligo therapy (antioxidants/vitamins/herbal medicine/traditional Chinese medicine), and/or topical vitiligo therapy including permanent or temporary tattoos within a minimum of 30 days prior to the first dose of study drug (Note: Camouflage and makeup may be used). - Participants treated with any phototherapy, including excimer (or other forms of laser therapy), within a minimum of 12 weeks prior to the first dose of study drug. - Participants have history of malignancy other than successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix. - Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, and aorto-coronary bypass surgery; - History of an organ transplant which requires continued immunosuppression; - History of gastrointestinal (GI) perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment; - Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded; - Uncontrolled thyroid disease; |
Country | Name | City | State |
---|---|---|---|
Canada | Centre de Recherche dermatologique du Quebec Metropolitain /ID# 228388 | Québec | Quebec |
Canada | Dr. Chih-ho Hong Medical Inc. /ID# 228403 | Surrey | British Columbia |
Canada | Research Toronto /ID# 228401 | Toronto | Ontario |
Canada | K. Papp Clinical Research /ID# 228877 | Waterloo | Ontario |
Canada | Wiseman Dermatology Research /ID# 228410 | Winnipeg | Manitoba |
France | Hopital Saint-Andre /ID# 228193 | Bordeaux | Gironde |
France | Hopital Henri Mondor /ID# 228198 | Creteil | |
France | HCL - Hopital Edouard Herriot /ID# 228194 | Lyon | Rhone |
France | Chu de Nice-Hopital L'Archet Ii /Id# 228192 | Nice | Alpes-Maritimes |
France | CHU Toulouse - Hopital Larrey /ID# 228196 | Toulouse | |
Japan | Nippon Medical School Hospital /ID# 230361 | Bunkyo-ku | Tokyo |
Japan | Yamanashi Prefectural Central Hospital /ID# 229441 | Kofu-shi | Yamanashi |
Japan | Nagoya City University Hospital /ID# 228725 | Nagoya shi | Aichi |
Japan | Tokyo Medical University Hospital /ID# 230288 | Shinjuku-ku | Tokyo |
Japan | Yamagata University Hospital /ID# 230362 | Yamagata-shi | Yamagata |
United States | Bellaire Dermatology Associates /ID# 228004 | Bellaire | Texas |
United States | Clearlyderm Dermatology /ID# 227993 | Boca Raton | Florida |
United States | Tufts Medical Center /ID# 228087 | Boston | Massachusetts |
United States | Medical University of South Carolina /ID# 228067 | Charleston | South Carolina |
United States | Michigan Center for Research Company /ID# 228054 | Clarkston | Michigan |
United States | Remington-Davis Clinical Research /ID# 229401 | Columbus | Ohio |
United States | Hamzavi Dermatology /ID# 228056 | Fort Gratiot | Michigan |
United States | University of Texas Health Science Center at Houston /ID# 229399 | Houston | Texas |
United States | Dawes Fretzin, LLC /ID# 227996 | Indianapolis | Indiana |
United States | University of California Irvine /ID# 229390 | Irvine | California |
United States | New Horizon Research Center /ID# 229403 | Miami | Florida |
United States | International Clinical Research - Tennessee LLC /ID# 228059 | Murfreesboro | Tennessee |
United States | Virginia Clinical Research, Inc. /ID# 228050 | Norfolk | Virginia |
United States | Park Avenue Dermatology, PA /ID# 229400 | Orange Park | Florida |
United States | Oregon Dermatology and Research Center /ID# 228007 | Portland | Oregon |
United States | Oregon Medical Res Center PC /ID# 228073 | Portland | Oregon |
United States | Stanford University /ID# 228000 | Redwood City | California |
United States | ForCare Clinical Research /ID# 228010 | Tampa | Florida |
United States | Essential Medical Research, LLC /ID# 228074 | Tulsa | Oklahoma |
United States | UMass Chan Medical School /ID# 228066 | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States, Canada, France, Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | At 24 weeks | |
Secondary | Percentage of Participants Achieving F-VASI 75 (= 75% Improvement in F-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | At 24 weeks | |
Secondary | Percentage of Participants Achieving F-VASI 50 (= 50% Improvement in F-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3. | At 24 weeks | |
Secondary | Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (= 50% Improvement in T-VASI From Baseline) | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | At 24 weeks | |
Secondary | Percent Change From Baseline in T-VASI | The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area [BSA]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100. | At 24 weeks | |
Secondary | Change From Baseline in the Vitiligo Quality-of-Life (VitiQoL) Instrument Total Score | The VitiQoL is a validated questionnaire used in clinical trials to assess stigma-related vitiligo impacts. The VitiQoL uses subject-elicited social, affective, and behavior items, asking the subject's appraisal of the vitiligo-related impacts over the last month. Fifteen items are scored on a 7-point scale ranging from 0 ("Not at all") to 6 ("All of the time"). Item scores (0 to 6) are summed to provide a total score range of 0 to 90; higher scores indicate greater impairment of quality of life (QoL). | At 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04052425 -
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
|
Phase 3 | |
Completed |
NCT04057573 -
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
|
Phase 3 | |
Completed |
NCT04942860 -
The Evaluation of Vitiligous Lesions Repigmentation After Topical Administration of Methotrexate in Patients With Active Vitiligo
|
Phase 3 | |
Recruiting |
NCT06113328 -
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
|
Phase 2 | |
Recruiting |
NCT01377077 -
Punchgrafting Techniques for Vitiligo
|
Phase 4 | |
Completed |
NCT04487860 -
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
|
Phase 2 | |
Active, not recruiting |
NCT04811326 -
Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation
|
Phase 4 | |
Terminated |
NCT03022019 -
ReNovaCell in Non-segmental Vitiligo
|
N/A | |
Completed |
NCT03247400 -
The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05990309 -
ASSESSMENT OF TRISTETRAPROLIN EXPRESSION IN LESIONAL SKIN OF PATIENTS WITH NON SEGMENTAL VITILIGO
|
N/A |